Revelation Biosciences Inc (NASDAQ: REVB) announced that a recently completed exploratory biomarker analysis confirmed clinical development plans for REVTx-300 in treating chronic kidney disease (CKD) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback